Novavax Inc.

Last updated September 27, 2026

Organization details

Legal name
Novavax Inc.
Ownership
Public
Status
Active
Headquarters country
United States
Ticker symbol
NVAX
Primary stock exchange
Nasdaq

Identifiers

SEC CIK
0001000694

Board of directors

Chief executives

John C. Jacobs · President and CEO
Since January 2023

Board connections

6 of this board's directors also sit on 10 other boards.

Network of Novavax Inc.'s board connections Ardelyx Inc. Ardelyx Inc. Aldeyra Therapeutics Inc. Aldeyra Therapeutics I... Corcept Therapeutics Incorporated Corcept Therapeutics I... Crescent Biopharma Inc. Crescent Biopharma Inc... Fulcrum Therapeutics Inc. Fulcrum Therapeutics I... Lunai Bioworks Inc. Lunai Bioworks Inc. MaxCyte Inc. MaxCyte Inc. Opus Genetics Inc. Opus Genetics Inc. Sagimet Biosciences Inc. Sagimet Biosciences In... Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals... David M. Mott David M. Mott Gregg H. Alton Gregg H. Alton Margaret G. Mcglynn Margaret G. Mcglynn Rachel K. King Rachel K. King Richard Douglas Richard Douglas Richard J. Rodgers Richard J. Rodgers Novavax Inc.
Shared director Other board Same sector

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months
$0
0 purchases by 0 insiders
Sold, last 12 months
$0
0 sales by 0 insiders
Date Insider Transaction Shares Price Value
Dec 11, 2024 Casey Mark J Officer (EVP, Chief Legal Officer) Option exercise +41,900 — —
Dec 11, 2024 Casey Mark J Officer (EVP, Chief Legal Officer) Shares withheld for tax −12,713 $8.82 $112,129
Aug 19, 2024 Trizzino John Officer (EVP, CCO and CBO) Option exercise +655 — —
Aug 19, 2024 Trizzino John Officer (EVP, CCO and CBO) Shares withheld for tax −317 $13.90 $4,406
Aug 16, 2024 Kelly James Patrick Officer (EVP, CFO and Treasurer) Option exercise +2,367 $12.96 $30,676
Aug 16, 2024 Kelly James Patrick Officer (EVP, CFO and Treasurer) Shares withheld for tax −1,223 $12.96 $15,850
Jun 21, 2024 James F. Young Director Open-market sale −7,500 $14.09 $105,675
Jun 18, 2024 James F. Young Director Open-market sale −6,393 $13.62 $87,073
Jun 18, 2024 James F. Young Director Open-market sale −1,107 $14.28 $15,808
Jun 17, 2024 Dubovsky Filip Officer (President, R&D) Option exercise +1,404 $6.97 $9,786
Jun 17, 2024 Dubovsky Filip Officer (President, R&D) Option exercise +12,500 $6.09 $76,125
Jun 17, 2024 Dubovsky Filip Officer (President, R&D) Open-market sale −12,500 $14.46 $180,750
Jun 17, 2024 Dubovsky Filip Officer (President, R&D) Open-market sale −1,404 $14.54 $20,414
Jun 12, 2024 Margaret G. Mcglynn Director Option exercise +6,670 — —
Jun 12, 2024 Gregg H. Alton Director Option exercise +6,670 — —

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.